Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.

Faivre-Finn, C.; Vicente, D.; Kurata, T.; Planchard, D.; Paz-Ares, L.; Vansteenkiste, J.; Spigel, D.; Garassino, M.; Reck, M.; Senan, S.; Naidoo, J.; Rimner, A.; Wu, Yi-long; Gray, J.; Özgüroğlu, M.; Lee, K.; Cho, B.; Kato, T.; de Wit, M.; Newton, M.; Wang, Lu; Thiyagarajah, P.; Antonia, S.

doi:10.1016/j.jtho.2020.12.015

Public

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.

Shared by NobleBlocks on Nov 21, 2020 • 12:00 AM UTC

Authors:

C. Faivre-Finn

D. Vicente

T. Kurata

Abstract

BACKGROUND In the phase-3, placebo-controlled PACIFIC trial of patients with unresectable, stage III non-small-cell lung cancer (NSCLC) without disease progression after concurrent chemoradiotherapy (CRT), consolidative durvalumab was associated with significant improvements in the primary endpoints...

Subject

Medicine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!